2013年9月-2017年7月 华中科技大学同济医学院药学院 学士

2017年9月-2022年7月 中国科学院上海药物研究所药物设计学专业 博士

2022年8月-2025年8月 中山大学肿瘤防治中心 博士后

2025年9月-至今 中国科学院广州生物医药与健康研究院，副研究员

1. 国家自然科学基金委员会,青年科学基金项目（C类）[原青年科学基金项目]，82404017，核黄素代谢关键酶RFK及其产物FMN异常活化调控非小细胞肺癌对于KRAS G12C抑制剂先天耐药的功能与机制研究，2025-01-01至2027-12-31，30万元，在研，主持

2. 中国博士后科学基金第74批面上资助，2023M744025，甲羟戊酸通路代谢异常参与非小细胞肺癌对于KRAS G12C抑制剂先天耐药的功能和机制研究，2024-01至2026-01，8万元，在研，主持

3. 国家资助博士后研究人员计划B档，GZB20230904，18万元，主持

2022年度中国科学院地奥奖学金一等奖

2020-2021年度中国科学院大学三好学生

2017年度华中科技大学优秀毕业生

2017年华中科技大学与德国马尔堡大学药学学科优秀本科生交流项目

2016年度国家奖学金

1. Guowei Yin#*;Jing Huang#;Johnny Petela#;Hongmei Jiang;Yuetong Zhang;Siqi Gong;Jiaxin Wu;Bei Liu;Jianyou Shi*;Yijun Gao*;Targeting small GTPases: emerging grasps on previously untamable targets,pioneered by KRAS,Signal Transduction and Targeted Therapy,2023,8(1):212

2. Xiaobo Wang#;Jing Huang#;Fenglin Liu#;Qian Yu;Ruina Wang;Jiaqi Wang;Zewen Zhu;Juan Yu;Jun Hou;Joong Sup Shim;Wei Jiang;Zengxia Li;Yuanyuan Zhang*;Yongjun Dang*;Aurora A kinase inhibition elevates PD-L1 expression and compromises its anti-tumor efficacy,Journal of Clinical Investigation,2023,9(133):e161929

3. Jing Huang#;Xiaobo Wang#;Bing Li#;Shiyu Shen;Ruina Wang;Hongru Tao;Junchi Hu;Jin Yu;Hualiang Jiang;Kaixian Chen;Cheng Luo*;Yongjun Dang*;Yuanyuan Zhang*;L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression,Journal for ImmunoTherapy of Cancer,2022,10(6):e003957-e003957

4. Jinjin Peng#;Jiacheng Li#; Jing Huang#;Pan Xu;Huang Heming Huang;Yanjun Liu;Liang Yu;Yaxi Yang;Bing Zhou;Hualiang Jiang;Kaixian Chen;Yongjun Dang;Yuanyuan Zhang*;Cheng Luo*;Guangming Li*;p300/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization,Theranostics,2019,9(26):8344-8361

5. Fei Ye#;Jing Huang#;Hongbo Wang;Cheng Luo*;Kehao Zhao*;Targeting epigenetic machinery:Emerging novel allosteric inhibitors,Pharmacology & Therapeutics,2019,204: 107406

6. Liping Liao#,Wenzhen Dang#,Tingting Lin#,Jinghua Yu,Tonghai Liu,Wen Li,Senhao Xiao,Lei Feng,Jing Huang,Rong Fu,Jiacheng Li,Liping Liu,Mingchen Wang,Hongru Tao,Hualiang Jiang,Kaixian Chen,Xingxing Diao,Bing Zhou,Xiaoyan Shen*,Cheng Luo*. A potent PGK1 antagonist reveals PGK1 regulates the production of IL-1β and IL-6. Acta Pharm Sin B. 2022,12(11):4180-4192.

7. Jianfeng Wang#,Chen Wan#,Pan Xu#,Xiao Li,Yongning Lu,Jin Di,Xiaomao Yin,Hao Jiang,Jing Huang,Huan Xiong,Fei Ye,Jia Jin,Yu Chen,Yiqian Xie,Zhifeng Chen,Hong Ding,Hao Zhang,Rongfeng Liu,Hao Jiang,Kaixian Chen,Zhiyi Yao,Cheng Luo*,Yiran Huang*,Yuanyuan Zhang*,Jin Zhang*. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Theranostics. 2021,11(11):5387-5403.

8. Zhongya Sun#,Hao Zhang#,Yuanyuan Zhang#,  Liping Liao#,Wen Zhou#,Fengcai Zhang,Fulin Lian, Jing Huang,Pan Xu,Rukang Zhang,Wenchao Lu,Mingrui Zhu,Hongru Tao,Feng Yang,Hong Ding,Shijie Chen,Liyan Yue,Bing Zhou,Naixia Zhang,Minjia Tan,Hao Jiang,Kaixian Chen,Bo Liu,Chuanpeng Liu*,Yongjun Dang*,Cheng Luo*. Covalent inhibitors allosterically block the activation of Rho family proteins and suppress cancer cell invasion. Adv Sci (Weinh). 2020,7(14):2000098.

9. Olga Pelikh#,Pascal-L Stahr#, Jing Huang,Martin Gerst,Patrik Scholz,Henriette Dietrich,Natalie Geisel,Cornelia M Keck*. Nanocrystals for improved dermal drug delivery. Eur J Pharm Biopharm. 2018,128:170-178.